The U.S. life sciences industry entered 2026 with surprising momentum, following threats of tariffs and disrupted trade, NIH funding cuts, and a sluggish IPO market. Accounting for more than ...
NEW YORK, June 25, 2026 /PRNewswire/ -- Life sciences executives report they are demonstrating strong confidence in their own company performance and remain focused on executing disciplined growth ...
Executives report they are prioritizing growth discipline, AI value proof and resilience in the second half of 2026 NEW YORK, June 25, 2026 /PRNewswire/ -- Life sciences executives report they are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results